

Rainer Storb, MD
Fred Hutchinson Cancer Research Center

Clinical Research Division; Head, Transplantation Biology Program

Rainer Storb, MD, is a native of Germany where he attended the University of Freiburg Medical School. After graduation, he spent two years doing clinical training in Essen and Munich, and then three years doing research in Paris on a NATO Science Fellowship, working with Drs. Najean, Bernard and Bessis. In 1965, Dr. Storb traveled to Seattle on a Fulbright Fellowship and began work in the Division of Hematology at the University of Washington with Dr. E. Donnall Thomas. It was here that Dr. Storb participated in the birth of the Seattle marrow transplantation program. For the past 39 years, he has worked to develop new concepts in transplantation biology and apply them to patients. Studies included the demonstration of peripheral blood stem cells for allogeneic transplantation in the 1960s and 1970s, the importance of in vitro histocompatibility typing for outcome of related and unrelated transplants in the 1960s and 1970s, the definition of immunologic recovery after marrow transplantation, the development of conditioning programs for transplantation, uncovering the nature of graft-host tolerance, developing strategies of treating and preventing graft-vs-host disease, and studies on hematopoietic engraftment.

James O. Armitage, MD
University of Nebraska

Professor, Department of Internal Medicine
Joe Shapiro Distinguished Chair of Oncology

An internationally recognized authority on non-Hodgkin's lymphoma, Dr. James Armitage founded the bone marrow transplant program at UNMC in 1983. Bone marrow transplantation enables patients to receive higher doses of chemotherapy and radiation than otherwise possible. The procedure is now standard care and the most common form of transplantation for cancer patients. Of the 3,000 transplants performed at UNMC and the Nebraska Medical Center, 40 percent have been for non-Hodgkin's lymphoma. A graduate and former dean of UNMC's College of Medicine, Dr. Armitage is once again turning his focus to the classroom and laboratory, continuing his invaluable research.

Nelson J. Chao, MD, MBA
Duke University School of Medicine

Professor of Medicine, Research Professor of Global Health
Professor in Immunology, Professor in Pathology
Chief, Division of Cellular Therapy

My research interests are in two broad areas, clinical hematopoietic stem cell and cord blood transplantation and in the laboratory studies related to graft vs. host disease and immune reconstitution. On the clinical side we are currently conducting approximately 50 different clinical protocols ranging from preparatory regimens, supportive care studies and disease specific protocols. Most of these clinical studies are centered around studies of the sources of stem cells and the methods to improve the long term outcome. There are exploratory protocols for novel therapies such as dendritic cell therapy for several malignancies, antiangiogenesis therapy, graft engineering to prevent graft-versus-host disease and antigen specific T cells or non-specific NK cells to prevent relapse. Moreover a strong focus of the program is to develop cord-blood transplantation for adult patients with hematologic malignancies. The laboratory studies center on understanding the immunological events that occur with graft-vs-host disease and methods to prevent this disease. The current efforts focus on understanding murine reconstitution following transplantation, use of a peptide polymer to block MHC class II recognition of minor histocompatibility antigens, use of T cell engineering to prevent graft-versus-host disease at the same time preserving a graft-versus-malignancy effect.

Edmund K. Waller, MD, PhD
Emory University/Winship Cancer Institute

Director, Bone Marrow Stem Cell Transplant Center
Director, Division of Stem Cell Transplantation Immunotherapy

Dr. Waller completed his undergraduate degree at Harvard University in 1978, his MD-PhD degree at Cornell-Rockefeller in 1985, and his clinical training in Oncology at Stanford University in 1991. Dr. Waller has extensive experience in designing early phase clinical trials and enrolling cancer patients on therapeutic clinical trials. His research is funded by the National Institutes of Health (NIH) including the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute **(**NHLBI**)**. He is also funded by the National Marrow Donor Program**®** **(**NMDP**),** the Leukemia & Lymphoma Society (LLS), and the American Society of Hematology (ASH). Dr. Waller's research focus is improving the efficacy and safety of autologous and allogeneic hematopoietic stem cell transplantation. In April 2014, Dr. Waller received NIH R01 research funding, covering a five year period, to investigate the mechanisms by which donor plasmacytoid dendritic cells (PDC) regulate the allo-reactivity of donor T-cells

Hanna Jean Khoury, MD
Emory University School of Medicine
Winship Cancer Institute

Dr. Hanna Jean Khoury earned his Medical Degree from the Université Catholique de Louvain in Brussels, Belgium, and then completed his residency in internal medicine at Memorial Medical Center in Savannah, Georgia, and his fellowship in hematology, medical oncology and bone marrow transplantation at Washington University in St. Louis, Missouri. Dr. Khoury is Professor of Hematology and Medical Oncology, Director of the Division of Hematology, the R. Randall Rollins Chair in Oncology, and a Georgia Cancer Coalition Distinguished Cancer Scholar.

Dr. Khoury's research interests focus on development of new drugs in leukemia, and in the identification of molecular markers that predict response to treatment and outcomes. As a recipient of the Georgia Cancer Coalition Distinguished Cancer Scholarship, Dr. Khoury established the Hematological Disorders Tissue Bank at Emory University. He conducted several leukemia and bone marrow transplant clinical trials, including pivotal trials that led to the approval of dasatinib, bosutinib, ponatinib and omacetaxine. Dr. Khoury's research efforts are reflected in over 125 peer-reviewed papers in high-impact journals such as *Cancer Cell*, *Science*, *New England Journal of Medicine, Blood* and *Journal of Clinical Oncology*.

John F. DiPersio, M.D., Ph.D.
Washington University School of Medicine

Dr. John F. DiPersio, Deputy Director, Alvin J. Siteman Cancer Center and Chief of the Division of Oncology at Washington University School of Medicine in St. Louis and the Virginia E. and Samuel J. Golman Professor of Medicine.

Dr. DiPersio's research focuses on fundamental and translational aspects of leukemia and stem cell biology. These studies include identification of genetic abnormalities in human leukemias, understanding processes involving stem cell and leukemia cell trafficking, and clinical and translational programs in both leukemia/myelodysplastic syndrome and stem cell transplantation.

Dr. DiPersio is Chair of ASH Scientific Committee on Hematopoiesis, a member of the Board of Scientific Counselors (Clinical Science and Epidemiology) of the National Cancer Institute, and the 2013 recipient of the Daniel P. Schuster Distinguished Translational Investigator Award from Washington University, the 19th Annual AACR Joseph H.

Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research in 2014 and the 2014 recipient of the American Society of Hematology Mentor Award for Clinical Investigations.. He has authored or co-authored more than 275 publications and over 60 invited reviews and book chapters.

Dr. DiPersio received his M.D. and Ph.D. from the University of Rochester and his B.A. in Biology from Williams College. He completed an internship and residency at Parkland Memorial Hospital and The University of Texas Southwestern Medical Center in Dallas. After serving as chief resident at Parkland Memorial Hospital, Dr. DiPersio completed a fellowship in the Division of Hematology/Oncology at the University of California, Los Angeles (UCLA).

Kenneth C. Anderson, MD
Dana Farber Cancer Center



Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Kraft Family Professor of Medicine, Harvard Medical School

Novel Biologically Based Therapies for Multiple Myeloma

Our recent advances in genomics and proteomics in multiple myeloma (MM) have increased our understanding of disease pathogenesis, helped to identify novel therapeutic targets, and provided the scientific rationale for combining targeted therapies to increase tumor-cell cytotoxicity and abrogate drug resistance. Specifically, gene microarray profiling has shown major differences between normal plasma cells and cells from monoclonal gammopathy of unclear significance (MGUS) and MM cells, with further modulations within MM cells and in cells progressing to plasma cell leukemia. Therefore, we have profiled individual patients newly diagnosed with MM in order to tailor targeted therapy for them; it is likely that cocktails of therapeutics will be needed to overcome resistance.

Sagar Lonial, MD
Emory University/Winship Cancer Institute

Vice Chair of Clinical Affairs, Department of Hematology and Medical Oncology

Dr. Lonial is a trained bone marrow transplant physician with an interest in molecular therapy for lymphoma and myeloma. His lab work is evaluating the combination of new molecular targeted agents for B-cell cancers, as well as methods to enhance immunity following allogeneic or autologous stem cell transplant.

Richard F. Ambinder, MD, PhD
Sidney Kimmel Comprehensive Cancer Center

Director, Division of Hematologic Malignancies, Program Leader, Hematologic Malignancies and Bone Marrow Transplant, James B. Murphy Professor
Professor of Oncology, Professor of Medicine, Professor of Pathology

Virus-associated tumors are among the most common malignancies in certain populations and certain regions. Thus, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients). New approaches to prevention, diagnosis or treatment might thus directly impact on the world's cancer problem in an important way.

Jing Chen, PhD
Emory University School of Medicine
Winship Cancer Institute

Co-Director, Experimental Therapeutics Program in Leukemia

Jing Chen, PhD, is an Associate Professor of Hematology and Medical Oncology at the Winship Cancer Institute of Emory, Emory University School of Medicine. He obtained his PhD in Biochemistry and Cell Biology at Emory University, and was trained as an HHMI Postdoctoral Fellow in Dr. Gary Gilliland's laboratory at Harvard Medical School before joining Winship Cancer Institute as an Assistant Professor in 2004. Dr. Chen is interested in the role of post-translational modifications including phosphorylation, acetylation and ubiquitination in human cancers, with a particular focus on oncogenesis, tumor metastasis and cancer metabolism. Dr. Chen has extensive publications in major peer-reviewed journals such as Science Signaling, Cancer Cell, Journal of Clinical Investigation, PNAS and Blood. Dr. Chen has earned numerous prestigious awards including American Cancer Society Basic Research Scholar Award, Leukemia and Lymphoma Society Scholar Award and Georgia Cancer Coalition Distinguished Cancer Scholar Award. His research is funded by NIH, American Cancer Society, Leukemia and Lymphoma Society and other notable foundations. Dr. Chen also serves as a Reviewer in the Cancer Drug Discovery panel of Grant Review Committee, American Cancer Society.

Amelia Langston, MD
Emory University School of Medicine
Winship Cancer Institute

Medical Director and Section Chief
Bone Marrow Transplant Program at the Winship Cancer Institute

Dr. Langston received her BA from Williams College, Williamstown, Massachusetts. She received her MD from Washington University, St. Louis, Missouri. She completed her residency in Internal Medicine at Duke University Medical Center, Durham North Carolina, followed by a Medical Oncology fellowship at the University of Washington Hospitals.

Dr. Langston's research interests include novel strategies for autologous and allogeneic stem cell transplantation, use of biologically targeted agents for antileukemic therapy, and prevention and treatment of opportunistic infections in immunocompromised patients.

Jonathan L. Kaufman, MD
Emory University School of Medicine
Winship Cancer Institute

Medical Director of the Ambulatory Infusion Centers
Associate Vice-Chair for Quality Hematology and Medical Oncology

Dr. Kaufman earned his Medical Degree from the Medical College of Georgia in Augusta. He subsequently completed his Residency in Internal Medicine and his Fellowship in Hematology and Oncology at Emory University.

Dr. Kaufman is an active clinical and translational researcher in the fields of multiple myeloma, amyloidosis, and bone marrow transplant.



Frederick R. Appelbaum, MD
Fred Hutchinson Cancer Research Center

Director, Clinical Research
Seattle Cancer Care Alliance, Executive Director,

University of Washington School of Medicine
Professor of Medicine
Head, Division of Medical Oncology

Dr. Appelbaum's group works to develop an improved understanding of the biology of acute myeloid leukemia (AML) and using this knowledge to create novel therapeutic approaches. In collaboration with the Southwest Oncology group, we have found that MDR1 mediated drug efflux in AML is increased in older patients and in patients with recurrent disease, and is tightly associated with drug resistance. They have completed studies showing an advantage of the use of MDR1 inhibition in patients with recurrent AML and are currently conducting clinical trials in the up-front treatment of older patients. In addition, they have identified novel compounds that inhibit not only drug efflux but the effects of BCL-2 overexpression and are attempting to define the optimal way in which to apply such therapy.